The Generic Pharmaceutical Association has announced its support of the U.S. Drug Enforcement Administration’s eighth annual National Prescription Drug Take-Back Day, taking place April 26 at local take-back sites across America.
CVS/pharmacy is teaming up with The Partnership at Drugfree.org to create a community donation program through which local police departments can apply to receive a drug collection unit to help their communities safely dispose of unwanted medications, including controlled substances, the pharmacy retailer announced on Thursday.
This week, 49 members of the U.S. House of Representatives urged Health and Human Services Secretary Kathleen Sebelius to adopt a one-year transition period for states to implement the July 2014 average manufacturer price-based federal upper limits.
By adding complementary specialty medication offerings to their generic drug businesses, manufacturers can add instant value and counteract the margin compression that is currently occurring as a result of high generic drug utilization.
Mylan on Friday announced that Supreme Court Chief Justice John Roberts has denied Teva's application for an injunction seeking to prevent Mylan's launch of a generic version of Copaxone (glatiramer acetate injection) pending the Supreme Court's decision on Teva's appeal.
Actavis and Forest Laboratories on Thursday announced that they have each received a request for additional information from the Federal Trade Commission in connection with Actavis' pending acquisition of Forest.
Evidence-based interventions at the local and national levels provide promising strategies for reducing racial and ethnic health disparities related to HIV infection rates, immunization coverage, motor vehicle injuries and deaths, and smoking, according to a new report by the CDC's Office of Minority Health and Health Equity released Thursday.
A new study in the American Journal of Preventive Medicine analyzing weekly patterns in health-related Google searches reveals a recurring pattern that could be leveraged to improve public health strategies.
Rates of five major diabetes-related complications have declined substantially in the last 20 years among U.S. adults with diabetes, according to a study by the Centers for Disease Control and Prevention, published in the current issue of the New England Journal of Medicine.
Mylan announced the launch of Xulane (norelgestromin/ethinyl estradiol transdermal system 150/35-mcg per day), the generic version of Ortho Evra (norelgestromin/ethinyl estradiol transdermal system 150/35-mcg per day) from Janssen Pharmaceuticals.
Teva Pharmaceutical announced that its U.S. subsidiary has entered into a settlement with Pfizer related to Teva's generic version of Celebrex (celecoxib) 50-, 100-, 200- and 400-mg capsules in the United States.
Cases of diabetes and pre-diabetes in the United States have nearly doubled since 1988, suggests new research released Tuesday from the Johns Hopkins Bloomberg School of Public Health, with obesity apparently to blame for the surge.
Actavis on Tuesday announced that it has entered into an agreement with Mylan and Famy Care to settle all outstanding patent litigation related to Mylan's generic version of Generess FE (norethindrone, ethinyl estradiol and ferrous fumarate chewable tablets).
Total spending on U.S. medicines increased 1% on a real per capita basis in 2013, while the use of healthcare services overall rose for the first time in three years, according to a new report issued today by the IMS Institute for Healthcare Informatics.
Prosonix, a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines by Design, on Tuesday announced that it has entered into a global licensing agreement with Mylan for its leading inhaled respiratory products, PSX1001 and PSX1050.
Now available online, the Drug Enforcement Administration National Prescription Drug Take-Back Day collection site locator allows consumers to search for a nearby location to dispose of unneeded medications on Saturday, April 26, 2014, the National Association of Boards of Pharmacy announced Wednesday.
Mylan on Friday confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan settling patent litigation in connection with Mylan's filing of an abbreviated new drug application with the Food and Drug Administration for frovatriptan succinate tablets, 2.5 mg.